Ultragenyx
$ 21.91
-6.01%
05 Jun - close price
- Market Cap 2,295,784,000 USD
- Current Price $ 21.91
- High / Low $ 23.41 / 21.74
- Stock P/E N/A
- Book Value -2.41
- EPS -6.10
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -6.08 %
- 52 Week High 42.37
- 52 Week Low 18.29
About
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is headquartered in Novato, California.
Analyst Target Price
$52.05
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-12 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-13 | 2024-11-05 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -1.54 | -1.29 | -1.81 | -1.17 | -1.57 | -1.39 | -1.4 | -1.52 | -2.03 | -1.52 | -2.23 | -2.25 |
| Estimated EPS | -1.46 | -1.17 | -1.21 | -1.32 | -1.64 | -1.27 | -1.47 | -1.63 | -1.72 | -1.61 | -2.01 | -2.02 |
| Surprise | -0.08 | -0.12 | -0.6 | 0.15 | 0.07 | -0.12 | 0.07 | 0.11 | -0.31 | 0.09 | -0.22 | -0.23 |
| Surprise Percentage | -5.4795% | -10.2564% | -49.5868% | 11.3636% | 4.2683% | -9.4488% | 4.7619% | 6.7485% | -18.0233% | 5.5901% | -10.9453% | -11.3861% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RARE
2026-06-06 07:39:45
BNP Paribas Financial Markets significantly increased its stake in Ultragenyx Pharmaceutical (NASDAQ:RARE) during the fourth quarter, acquiring an additional 330,031 shares. This move, along with investments from other institutions, highlights strong institutional ownership, with 97.67% of RARE shares held by such entities. Despite this, Ultragenyx reported a quarterly loss and revenue below estimates, and insiders have recently sold shares, contributing to a 6% drop in the stock.
2026-06-06 05:39:34
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its stock rating upgraded by Wall Street Zen from "strong sell" to "sell." Despite the upgrade, the biopharmaceutical company reported a larger-than-expected loss in its latest quarter, missing both earnings and revenue estimates. The stock has been trading below its 50-day and 200-day moving averages, and institutional investors have recently adjusted their holdings.
2026-06-05 11:55:00
Ultragenyx Pharmaceutical Inc. (RARE) is gaining institutional confidence, particularly for its GTX-102 drug used to treat Angelman syndrome. Cantor Fitzgerald raised its price target for RARE to $96, citing favorable testing parameters and a robust Phase 3 trial design. While Wedbush maintained a Neutral rating due to revenue underperformance, it still expects the company to achieve profitability by 2027 and foresees positive outcomes from upcoming PDUFAs and ASPIRE results.
2026-06-05 08:10:13
Ultragenyx Pharmaceutical's analyst price target has slightly decreased to $52.05 per share, reflecting diverse views on its gene therapy pipeline, particularly GTX-102. Bullish analysts emphasize the potential of GTX-102 and the existing commercial business, while bearish sentiment points to execution risks and conservative assessments of future programs. The company reaffirmed its revenue guidance for 2026 and aims for profitability by 2027, bolstered by FDA approvals and ongoing clinical trial advancements.
2026-06-04 20:10:02
Kuehn Law, PLLC is investigating Ultragenyx Pharmaceutical Inc. (RARE) for potential breaches of fiduciary duties by its officers and directors. The investigation stems from allegations in a federal securities lawsuit that insiders misrepresented the potential and risks of setrusumab, specifically that increased bone density did not correlate with reduced fracture rates. Shareholders who owned RARE prior to August 3, 2023, are encouraged to contact the law firm.
2026-06-04 18:39:46
Ultragenyx Pharmaceutical Inc. announced that its CEO, Emil Kakkis, M.D., Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The company, focused on rare and ultra-rare genetic diseases, will make the webcast of the event accessible on its website. This participation highlights Ultragenyx's continued engagement with the financial community and its commitment to developing novel therapies.
